Most Read Articles
Pearl Toh, 6 days ago
A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).
Roshini Claire Anthony, 4 days ago

Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.

Vertical sleeve gastrectomy linked to higher postsurgery acute pancreatitis risk

12 Oct 2018

Vertical sleeve gastrectomy (VSG) confers a higher risk of acute pancreatitis (AP) than Roux-en-Y gastric bypass surgery (RYGB), particularly in young patients and in those with gallstones, reports a recent study.

Drawing from the National Readmission Database of the USA, researchers compared the rates of AP within 6 months before and after surgery among morbidly obese participants who underwent VSG (n=205,251), RYGB (169,973) or hernia repair (HR; controls; n=16,845). Each group was further divided into pre- and postsurgery cohorts, depending on the timing of patient discharge.

Presurgery AP was highest in the HR group (0.17 percent), while postsurgery AP was most prevalent in patients who received VSG (0.21 percent). More than half (58.3 percent) of AP readmission occurred within 30 days after VSG.

After complete adjustments for confounding variables such as age, sex and comorbidities, weighted logistic regression analysis showed that the risk of post- vs presurgery AP was highest in patients who received AP (adjusted odds ratio [OR], 5.16; 95 percent CI, 3.11–8.56; p<0.001).

The post- vs presurgery AP risk associated with RYGB was also significantly elevated, but to a lesser degree (adjusted OR, 2.26; 1.33–3.87; p=0.003). No increase in AP risk following HR was observed.

Moreover, when researchers compared the types of surgery with each other, they showed that VSG resulted in a significantly higher post- vs presurgery AP risk than RYGB (adjusted OR, 2.28; 1.10–4.73; p=0.03) and HR (adjusted OR, 7.58; 2.09–27.58; p=0.002). There was no significant difference between RYGB and HR (adjusted OR, 3.33; 0.91–12.18; p=0.07).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).
Roshini Claire Anthony, 4 days ago

Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.